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ABSTRACT 
Drug-induced Psoriasis is one among the common etiological factors of Psoriasis reported worldwide. Familiar drugs known to cause psoriasiform 
eruptions include Anti-malarials, Beta blockers, NSAIDs, Lithium. etc. Certain antihypertensives like ACE inhibitors, diuretics are also documented 
to have caused psoriatic episodes.  
A 57 y old South-Indian male patient with a history of Hypertension, Diabetes Mellitus, Atrial Fibrillation for 4 y; was on antihypertensive therapy 
for Hypertension and Atrial Fibrillation with proponolol for past 2 y and metoprolol initially. He was presented to the hospital two weeks after 
switching on to Metoprolol therapy for chief complaints of erythematous scaly lesions especially over both the extremities and paronydrial 
appearance of nails. Initially, he was on Propranolol therapy which was then shifted to Metoprolol due to an appearance of oral lesions in the mouth. 
Metoprolol was now discontinued and switched on to Atenolol. After 1-2 w of therapy with Atenolol, the lesions were found to disappear and no 
recurrence of psoriatic conditions were found. 
Proper reviewing of medical history for any allergic reactions and the optimization of drug therapy through Therapeutic Drug Monitoring could be 
initiated by Clinical Pharmacist in order to avoid such drug-induced flares.  
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Psoriasis is defined on a clinical basis as chronic, relapsing, 
remitting papulosquamous eruption with typical localization on 
the extensor surfaces like elbows and knees involving scalp, 
genitalia or nails and other sites [1-4]. Etiology includes 
environmental and genetic factors. Erythematous, scaly skin 
lesions along with additional manifestations in nails and joints 
are commonly present. Most common form is plaque psoriasis. 
Pustular, guttate, inverse and erythrodermic psoriasis are the 
atypical forms [5-8]. 
It is clearly known that individual with psoriasis have an increased risk 
of hypertension and β blockers anti-hypertensive medications, cause 
psoriasis at its adverse levels. Psoriasis and hypertension are found to be 
concomitantly related and most medications used in treating the co-
morbidities are found to aggravate psoriasis among which β blockers are 
more common [12-14]. Correlation mechanism of Psoriasis which is 
induced by β blockers is explained in chart I. 
Biological mode of a possible mechanism for drug provoked psoriasis 
is illustrated in Chart II [18-20]. 
 
 
Chart I: Correlation mechanism of psoriasis and hypertension [15-17] 
 
Drug-induced psoriasis is found to act in two ways. One is where the 
psoriasis is due to an adverse effect of the drug and which subsides on 
the gradual withdrawal of the drug. Second is an aggravation of the 
persisting psoriatic condition where withdrawal of drug has no much 
effect [21-24]. Latency period from ingestion of β blockers to psoriatic 
flares varies from several days to 12 mo in patients with psoriasis [25]. 
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Chart II: Relationship of β blockers and psoriasis in biological and immunological aspects 
 
CASE REPORT 
A 57 y old South-Indian Male patient was admitted to the hospital 
with chief complaints of shredding of scales which are silver, 
especially those present at his extremities since 3 d. There were 
generalized erythema scaling with fine scales all over the body. His 
nails showed paronydrial appearance as depicted in fig. I. There was 
no history of any such family reports. He had a medical history of 
Hypertension, Type II Diabetes mellitus and Atrial Fibrillation for 
which he was on medication for the past 4 y. He was a chain smoker 
and a functional alcoholic with chewing of Tobacco gums daily. He 
had a blood pressure of 160/110 mmHg. There was a previous 
history of oral lesions with propranolol therapy which was 
discontinued due to poor control in Blood Pressure levels and 
lesions in the mouth. The patient was on treatment with anti-
hypertensive and anti-arrhythmic drugs for the past 4 y and 2 y for 
his atrial fibrillation. Propranolol and other calcium channel 
blockers were indicated. Propranolol40 mg orally twice a day was 
switched on to metaprolol 100 mg orally daily due to the low 
therapeutic outcome from propranolol after 2 y of therapy. With 
regards to General, Physical and Systemic examination, the patient 
was on Erythematous Psoriasis due to Metoprolol. Lab examinations 
were performed from time to time as shown in table I. Other 
medications which were taken by the patients included Metfromin 
(500 mg), Glibenclamide (1 mg), Verapamil (200 mg). Metoprolol 
was withdrawn immediately on knowing the etiology and topical 
corticosteroids (1% Hydrocortisone) was prescribed. Methotrexate 
was prescribed initially with which reducation in scales and 
eruptions were found. Later on he was prescribed with Atenolol 50 
mg for his hypertensive and atrial fibrillation condition. 
  
Table 1: Laboratory values of the patient 
Diagnostic parameters  Patients value Normal values  Inference  
PCV 43.4% 41-59% Within limits 
WBC 15.60x109 4.5-11.0x10/l 9 Increased  /l 
RBC 5.07x10[12]/l 3.8-4.8 x10[12]/l Increased  
Hemoglobin 11.1 g/dl 12-17 g/dl Decreased  
MCV 95.2fL 76-96fL Within limits  
MCH 31.3pg 27-32 pg Within limits  
MCHC 32.8 31-35 Within limits  
Platelets  2.19 x 10 1.5-4x 109 Within limits  9 
Lymphocytes 21.3% 20-40% Within limits  
ESR 09 min, 26 sec 5-20 mm/hr Within limits  
RBS 288 mg/dl 80-140m/dl Increased  
Urea 26.9 mg/dl 7-18 mg/dl Increased  
Creatinine 0.9 mg/dl 0.6-1.3 mg/Dl Within limits  
Cholestrol 218 mg 0-400 mg Within limits  
Blood group O+ve   
BMI 27.8   
VDRL -ve   
SGOT 18 U/l 15-17 U/l Increased  
SGPT 62 U/l 30-65 U/l Within limits  
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One of the most common side effects of β blockers is psoriasiform drug 
eruptions. The documented adverse drug reactions of metoprolol 
include Acute Generalized Exanthematous pustulosis (AGEP), Purpura, 
Bullous Pemphigoid, Steven-Johnson’s syndrome, immune 
thrombocytopenia. The mechanism involves impairment in lymphocyte 
transformation with a gradual decrease in cyclic adenosine 
monophosphate (cAMP) and cell proliferation. Others like ACE 
inhibitors, frusemide, biguanides etc, could also cause psoriasiform 
eruptions all over the body [26, 27]. With the discontinuation of 
metoprolol, the lesions and eruptions were found to be reduced and 
there was no reappearance of lesions when treated with atenolol in its 
initial stage. This clearly depicts that the above case is drug-induced 
erythematous psoriasis with the involvement of nails and extremities. 
His history of events with beta-blocker therapy is given in table II. 
  
 
Fig. I: Erythematic lesions on both the extremities of the patient with metaprolol drug therapy 
 





Shift from one medication to another Comments  
1 0-2 y Initiation of propranolol No much therapeutic effect obtained, presence of oral lesions in mouth 
2 1 w Discontinuation of propranolol and 
initiation of metoprolol  
Rash and itching also present in body parts 
3 1-2 w Continuation of metoprolol  Raising of psoriasiform eruptions especially at extremities with scales 
and paronydrial appearance of nails  
4 1-2 w  Discontinuation of metoprolol  Resolving of rashes  
5  4 w  Initiation of atenolol  Psoriasis type lesions and scales were resolved  
 
CONCLUSION 
Aggravation or exacerbation of drug-induced psoriasis could be 
reduced by discontinuing the intake of the particular drug. A sound 
knowledge of the drugs which leads to such conditions could be 
known in prior to health professionals and individualized therapy 
could be done in such situations. Timely and propitious detection and 
withdrawal of all imminent causes is crucial for a positive outcome.  
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